Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609275 | 1.00 | USP2 (0.41) | USP2SMN1; SMN2NR1H2KDM1ADDB1 | |
| SCHEMBL27005788 | 1.00 | USP2 (0.41) | USP2SMN1; SMN2NR1H2KDM1ADDB1 | |
| SCHEMBL15719645 | 0.84 | NR1H2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL21597767 | 0.84 | NR1H2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL31722107 | 0.84 | NR1H2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL30954981 | 0.84 | NR1H2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL961345 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL15896820 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL31749833 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2NR1H2USP30MEN1 | |
| SCHEMBL20356529 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2NR1H2USP30MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| WO-2025228828-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES | MERCK PATENT GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| CN-119998280-A | Pyrazolo [1,5-a ] pyridine derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499636-A2 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4495111-A1 | NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 | Arum Therapeutics Inc (KR) | 2025-01-22 | — | — | EP | disclosed |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536283-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011103091-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, NOD2, GPBAR1 | USP2 3822/4885SMN1; SMN2 2373/4885NR1H2 454/4885 |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | AGER, PSEN2, PSEN1 | USP2 3702/4885SMN1; SMN2 1405/4885NR1H2 249/4885 |
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM5, TRPM4 | USP2 4586/4885SMN1; SMN2 2214/4885NR1H2 1656/4885 |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, PSEN2, PSEN1 | USP2 3702/4885SMN1; SMN2 1405/4885NR1H2 249/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | USP2 2671/4885SMN1; SMN2 4425/4885NR1H2 410/4885 |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | USP2 4152/4885SMN1; SMN2 3214/4885NR1H2 775/4885 |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | USP2 2131/4885SMN1; SMN2 623/4885NR1H2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.